Lv41
508 积分 2023-03-26 加入
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
2小时前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
5天前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
5天前
已完结
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
5天前
已完结
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
5天前
已完结
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer
6天前
已完结
Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer
21天前
已完结
Pursuit of precision oncology in the treatment of metastatic hormone receptor–positive breast cancer: Making strides or barely moving?
22天前
已完结
Ribociclib plus Endocrine Therapy in Early Breast Cancer
1个月前
已完结
Ribociclib plus Endocrine Therapy in Early Breast Cancer
1个月前
已完结
皖公网安备34019202002308
